PDS Biotechnology (PDSB) Set to Release Earnings on Thursday

PDS Biotechnology (NASDAQ:PDSB) is projected to announce its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.09) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 19, 2026 at 8:00 AM ET.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05). On average, analysts expect PDS Biotechnology to post ($0.43) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.

PDS Biotechnology Trading Down 4.6%

PDSB opened at $1.03 on Wednesday. PDS Biotechnology has a 12-month low of $0.20 and a 12-month high of $1.79. The company has a debt-to-equity ratio of 2.73, a quick ratio of 0.57 and a current ratio of 0.57. The stock has a fifty day moving average of $0.94 and a 200-day moving average of $0.84.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PDSB. HC Wainwright reissued a “buy” rating on shares of PDS Biotechnology in a report on Wednesday, August 26th. Wall Street Zen raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Monday, October 5th. B. Riley Financial reaffirmed a “buy” rating and set a $4.00 price objective (up from $3.00) on shares of PDS Biotechnology in a research note on Thursday, October 29th. Finally, Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 28th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, PDS Biotechnology presently has an average rating of “Hold” and an average target price of $9.50.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s research is based primarily on its Versamune platform, a proprietary technology designed to stimulate targeted immune responses, including the activation of cancer-fighting T cells and natural killer cells. Its lead investigational product, PDS0101, is an immunotherapy candidate designed to target human papillomavirus type 16 (HPV16), a viral strain associated with several cancers.